RSC medicinal chemistry · 2026
Design, synthesis and pharmacological evaluation of 3H-spiro[benzofuran-2,4'-piperidine] IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Zhiwei, Zhang Qi, Chen Yun, Ning Yi, Zhang Q-I, Zhang Mengxiao, Liu Qiupei, Xue Yi, Tong Linjiang, Ding Jian, Xie Hua, Duan Wenhu
Аннотация
Interleukin-1 receptor-associated kinase 4 (IRAK4) has emerged as a promising target for the treatment of diffuse large B-cell lymphoma (DLBCL). Herein, we report the identification and structure-activity relationship studies of a new series of 3H-spiro[benzofuran-2,4'-piperidine] IRAK4 inhibitors designed to improve the pharmacokinetic properties of a previously identified series. The representative compound 13 showed strong inhibitory activity against IRAK4, significant antiproliferative effect against DLBCL cells, and improved pharmacokinetic properties. In addition, compound 13 effectively inhibited the activation of IRAK4 signaling pathway and induced DLBCL cell apoptosis. These results indicated that compound 13 was a promising lead compound for the development of anti-DLBCL agents.